TheranosticTrials.org

Clinical Trial · NCT03204123

PSMA PET Imaging of Recurrent Prostate Cancer

Overview

The purpose of this study is to see if a new diagnostic research agent named 68Ga-HBED-CC-PSMA can show prostate cancer on a PET/CT scan that cannot be seen on other standard imaging even when the PSA levels are very low.

Sponsor

Memorial Sloan Kettering Cancer Center

Phase

Phase 2

Contacts

Heiko Schöder, MD (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT03204123

Drug / Compound

PSMA-11

Isotope(s):
Target(s):
  • PSMA
Ligand Class: Small Molecules
Chelator: HBED-CC

Eligibility

Inclusion

  • For patients who have received additional treatment in the recurrent or metastatic setting: ° PSA ≥ 2 ng/ml above the most recent therapy nadir
  • Initially treated with definitive local therapy (surgery and radiation therapy are the most common treatments, but other treatments are also eligible)
  • Biopsy proven adenocarcinoma of the prostate
  • For patients initially treated with surgery, radiation therapy, brachytherapy, or cryotherapy:
  • Patient must be able to tolerate PET/CT or PET/MR imaging
  • Note: The most recent PSA value must be within 6 weeks of consent
  • PSA ≥ 0.2 ng/mL in at least two consecutive tests within 6 months of date of consent for patients

Exclusion

  • Patient with claustrophobia that would preclude PET/CT or PET/MR imaging or other contraindications to CT imaging.